Yul Ri Chung1, Hyun Jeong Kim2, Min Hye Jang3, So Yeon Park4,5. 1. Department of Pathology, Seoul National University College of Medicine, Seoul, Republic of Korea. 2. Department of Pathology, Seoul National University Bundang Hospital, 82 Gumi-ro 173 Beon-gil, Bundang-gu, Songnam, Gyeonggi, 13620, Republic of Korea. 3. Department of Pathology, Yeungnam University Medical Center, Daegu, Republic of Korea. 4. Department of Pathology, Seoul National University College of Medicine, Seoul, Republic of Korea. sypmd@snu.ac.kr. 5. Department of Pathology, Seoul National University Bundang Hospital, 82 Gumi-ro 173 Beon-gil, Bundang-gu, Songnam, Gyeonggi, 13620, Republic of Korea. sypmd@snu.ac.kr.
Abstract
PURPOSE: Interaction between immune-regulatory proteins and tumor infiltrating lymphocytes (TILs) is complex, and their associations may have significant clinical implications. This study was designed to evaluate the relationships between immunomodulatory proteins and TIL subsets and their impact on prognosis in breast cancer. METHODS: 377 invasive breast cancer cases were selected, and immunohistochemistry was performed for HLA-A, HLA-ABC, and indoleamine 2,3-dioxygenase (IDO); CD4+, CD8+, and FOXP3+ T cells were counted in intratumoral and stromal areas for both absolute numbers as well as their ratios. RESULTS: While HLA-ABC and HLA-A expressions showed a positive correlation with CD8+ and FOXP3+ TIL infiltration, IDO expression showed a negative correlation with FOXP3+/CD4+ and FOXP3+/CD8+ T cell ratios. Expressions of HLA-ABC, HLA-A, and IDO shared an association with negative estrogen receptor status. Infiltration of CD4+, CD8+, and FOXP3+ TILs was significantly higher in tumors with high histologic grade, negative hormone receptor status, HER2 amplification, high Ki-67 index, and p53 overexpression. In survival analyses, increased CD4+ TIL infiltration was associated with better prognosis of the patients while other TIL subset infiltration and expression of immunomodulatory proteins had no prognostic significance. In subgroup analyses, high CD4+ TIL infiltration was revealed as an independent good prognostic factor in hormone receptor-negative subgroup while high FOXP3+/CD8+ T cell ratio was found to be an independent adverse prognostic factor in hormone receptor-positive subgroup, especially in luminal A subtype. CONCLUSION: CD4+ TIL subset and FOXP3+/CD8+ T cell ratio have different prognostic significance in breast cancer according to hormone receptor status.
PURPOSE: Interaction between immune-regulatory proteins and tumor infiltrating lymphocytes (TILs) is complex, and their associations may have significant clinical implications. This study was designed to evaluate the relationships between immunomodulatory proteins and TIL subsets and their impact on prognosis in breast cancer. METHODS: 377 invasive breast cancer cases were selected, and immunohistochemistry was performed for HLA-A, HLA-ABC, and indoleamine 2,3-dioxygenase (IDO); CD4+, CD8+, and FOXP3+ T cells were counted in intratumoral and stromal areas for both absolute numbers as well as their ratios. RESULTS: While HLA-ABC and HLA-A expressions showed a positive correlation with CD8+ and FOXP3+ TIL infiltration, IDO expression showed a negative correlation with FOXP3+/CD4+ and FOXP3+/CD8+ T cell ratios. Expressions of HLA-ABC, HLA-A, and IDO shared an association with negative estrogen receptor status. Infiltration of CD4+, CD8+, and FOXP3+ TILs was significantly higher in tumors with high histologic grade, negative hormone receptor status, HER2 amplification, high Ki-67 index, and p53 overexpression. In survival analyses, increased CD4+ TIL infiltration was associated with better prognosis of the patients while other TIL subset infiltration and expression of immunomodulatory proteins had no prognostic significance. In subgroup analyses, high CD4+ TIL infiltration was revealed as an independent good prognostic factor in hormone receptor-negative subgroup while high FOXP3+/CD8+ T cell ratio was found to be an independent adverse prognostic factor in hormone receptor-positive subgroup, especially in luminal A subtype. CONCLUSION: CD4+ TIL subset and FOXP3+/CD8+ T cell ratio have different prognostic significance in breast cancer according to hormone receptor status.
Entities:
Keywords:
Breast cancer; CD4; CD8; FOXP3; HLA; Indoleamine 2,3-dioxygenase (IDO)
Authors: Khalid El Bairi; Harry R Haynes; Elizabeth Blackley; Susan Fineberg; Jeffrey Shear; Sophia Turner; Juliana Ribeiro de Freitas; Daniel Sur; Luis Claudio Amendola; Masoumeh Gharib; Amine Kallala; Indu Arun; Farid Azmoudeh-Ardalan; Luciana Fujimoto; Luz F Sua; Shi-Wei Liu; Huang-Chun Lien; Pawan Kirtani; Marcelo Balancin; Hicham El Attar; Prerna Guleria; Wenxian Yang; Emad Shash; I-Chun Chen; Veronica Bautista; Jose Fernando Do Prado Moura; Bernardo L Rapoport; Carlos Castaneda; Eunice Spengler; Gabriela Acosta-Haab; Isabel Frahm; Joselyn Sanchez; Miluska Castillo; Najat Bouchmaa; Reena R Md Zin; Ruohong Shui; Timothy Onyuma; Wentao Yang; Zaheed Husain; Karen Willard-Gallo; An Coosemans; Edith A Perez; Elena Provenzano; Paula Gonzalez Ericsson; Eduardo Richardet; Ravi Mehrotra; Sandra Sarancone; Anna Ehinger; David L Rimm; John M S Bartlett; Giuseppe Viale; Carsten Denkert; Akira I Hida; Christos Sotiriou; Sibylle Loibl; Stephen M Hewitt; Sunil Badve; William Fraser Symmans; Rim S Kim; Giancarlo Pruneri; Shom Goel; Prudence A Francis; Gloria Inurrigarro; Rin Yamaguchi; Hernan Garcia-Rivello; Hugo Horlings; Said Afqir; Roberto Salgado; Sylvia Adams; Marleen Kok; Maria Vittoria Dieci; Stefan Michiels; Sandra Demaria; Sherene Loi Journal: NPJ Breast Cancer Date: 2021-12-01
Authors: Carmine De Angelis; Chandandeep Nagi; Cliff C Hoyt; Linying Liu; Kristin Roman; Chichung Wang; Yi Zheng; Jamunarani Veeraraghavan; Vidyalakshmi Sethunath; Paolo Nuciforo; Tao Wang; Anna Tsimelzon; Sufeng Mao; Susan G Hilsenbeck; Meghana V Trivedi; Maria Letizia Cataldo; Anne Pavlick; Antonio C Wolff; Britta Weigelt; Jorge S Reis-Filho; Aleix Prat; Carolina Gutierrez; Charles Kent Osborne; Mothaffar F Rimawi; Rachel Schiff Journal: Clin Cancer Res Date: 2019-10-25 Impact factor: 12.531
Authors: Maria C Svensson; Carl Fredrik Warfvinge; Richard Fristedt; Charlotta Hedner; David Borg; Jakob Eberhard; Patrick Micke; Björn Nodin; Karin Leandersson; Karin Jirström Journal: Oncotarget Date: 2017-07-21
Authors: Rashmi Verma; Andrew M Hanby; Kieran Horgan; Eldo T Verghese; Milene Volpato; Clive R Carter; Thomas A Hughes Journal: Breast Cancer Res Treat Date: 2020-06-23 Impact factor: 4.872
Authors: Julian Puppe; Tabea Seifert; Christian Eichler; Henryk Pilch; Peter Mallmann; Wolfram Malter Journal: Breast Care (Basel) Date: 2020-07-21 Impact factor: 2.860